Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK-A16037)
View/ Open
Publication Date
2020-12-01Author
Banerjee, S
Tovey, H
Bowen, R
Folkerd, E
Kilburn, L
McLachlan, J
Hall, M
Tunariu, N
Attygalle, A
Lima, JPDSN
Perry, S
Chatfield, P
Hills, M
Kaye, S
Attard, G
Dowsett, M
Bliss, JM
Type
Journal Article
Metadata
Show full item recordVersion of record
Subject
Science & Technology
Life Sciences & Biomedicine
Oncology
abiraterone
androgen receptor
CYP17 inhibitor
low grade serous
ovarian cancer
Research team
Clinical Trials & Statistics Unit
Medicine Drug Development Unit (Kaye)
Endocrinology
Language
English
License start date
2020-12-01
Citation
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12 pp. ? - ? (13)
Publisher
SAGE PUBLICATIONS LTD